Skip Navigation


European Heart Journal Advance Access originally published online on February 21, 2007
European Heart Journal 2007 28(5):522-524; doi:10.1093/eurheartj/ehl555
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/5/522    most recent
ehl555v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lowes, B. D.
Right arrow Articles by Blaxall, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lowes, B. D.
Right arrow Articles by Blaxall, B. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Gene expression profile of the recovering human heart

Brian D. Lowes1, Marc L. Baker2 and Burns C. Blaxall2,3,*

1 Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
2 Division of Cardiology, University of Rochester Medical Center, Rochester, NY 14642, USA
3 Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, NY 14642, USA

* Corresponding author. Tel: +1 585 273 1094; fax: +1 585 276 1914. E-mail address: burns_blaxall@urmc.rochester.edu

This editorial refers to ‘Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy’ {dagger} by J.L. Hall et al., on page 613

The first 10% of the full text of this article appears below.

Heart failure is a disease of increasing prevalence and poor prognosis. Current data indicate that 5-year survival following the diagnosis of heart failure is 50%, and patients with end-stage disease face a 1-year survival rate of 50%. Recent predictions suggest that heart failure will become the leading cause of all disability by 2020. For patients with refractory end-stage heart failure, there are few options for effective treatment. Although cardiac transplantation provides the best therapeutic outcome for end-stage HF, substantial limitations of this surgical intervention include an extremely limited supply of acceptable donor hearts, having reached a plateau of less than 3000 per year worldwide.

Left ventricular assist device (LVAD) support of end-stage heart failure patients was originally approved as a bridge to cardiac transplant, and recent reports suggest improved outcomes in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy
Jennifer L. Hall, Emma J. Birks, Suzanne Grindle, Martin E. Cullen, Paul J. Barton, James E. Rider, Sangjin Lee, Subash Harwalker, Ami Mariash, Neeta Adhikari, Nathan J. Charles, Leanne E. Felkin, Sean Polster, Robert S. George, Leslie W. Miller, and Magdi H. Yacoub
EHJ 2007 28: 613-627. [Abstract] [Full Text]